Dr. Chang の 血液腫瘤筆記本

Study drug

Trial

Study group

Intervention

Result

Tamoxifen

NSABP P-1

1. 1.      healthy women aged 60 years or older
2. 2.      aged 35-59 with a 1.7% or greater cumulative 5-year risk for developing breast cancer
3. 3.      with a history of LCIS

tamoxifen, 20 mg daily for 5 years, or placebo

7Y f/u

1. 1.      decreased 43% breast cancer risk
2. 2.      NNT: 47

Tamoxifen

IBIS-I

aged 35-70 years at increased risk for breast

cancer

tamoxifen or placebo for 5 years

6Y f/u

29% risk reduction of breast cancer (invasive or DCIS)

Raloxifene

NSABP P-2 (STAR)

1. 35 years or older at

increased risk for invasive breast cancer as determined by the modified Gail model

2. with a personal history of LCIS

20 mg/day tamoxifen or 60 mg/day raloxifene

1. Raloxifene was shown to be about 76% as effective as tamoxifen in reducing the risk of invasive breast cancer

2. But raloxifene has lower adverse effects

Exemestane

MAP.3

Postmenopausal women at increased risk of breast cancer

Exemestane vs. placebo

3Y f/u

1. 1.      65% risk reduction in breast acncer
2. 2.      NNT: 27

Anastrozole

IBIS-II

Postmenopausal women (40 to 70 years) at high risk of breast cancer (due to family history, atypia, or lobular carcinoma in situ, or breast density)

anastrozole or placebo for 5 years

5Y f/u

53% risk reduction in breast cancer